Charles Kaplan

Title: Charles Kaplan: Innovator in Cancer Treatment

Introduction

Charles Kaplan is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of cancer treatment through his innovative research and development of antibodies. With a total of 3 patents, Kaplan's work focuses on the detection and treatment of cancer using B7-H4 antibodies.

Latest Patents

Kaplan's latest patents include groundbreaking work on B7-H4 antibodies and their methods of use. One of his patents provides antibodies and antigen-binding fragments that specifically bind to human B7-H4. These anti-B7-H4 antibodies are useful for detecting B7-H4 through immunohistochemistry (IHC). Additionally, the patent outlines methods for treating cancer where increased B7-H4 has been detected, by administering a therapeutic anti-B7-H4 antibody or antigen-binding fragment. Another patent details antibodies that not only bind to human B7-H4 but also increase T cell proliferation and interferon-gamma production, while depleting B7-H4 expressing cells via ADCC activity. This patent also provides methods for treating disorders, such as cancer, by using these specific antibodies.

Career Highlights

Charles Kaplan is currently associated with Five Prime Therapeutics, Inc., where he continues to advance his research in antibody development. His work has positioned him as a key figure in the biotechnology sector, particularly in the fight against cancer.

Collaborations

Kaplan collaborates with notable colleagues, including Majid Ghoddusi and Kathy Miller, who contribute to his research efforts and innovations in the field.

Conclusion

Charles Kaplan's contributions to cancer treatment through his innovative patents and collaborations highlight his importance in the biotechnology industry. His work with B7-H4 antibodies represents a significant advancement in the detection and treatment of cancer.